Drug intelligence / Profile preview

meflin + IL-33 decoy ST2

Development stage: Preclinical
Lead developer: Adjuva Bio
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

Adjuva Bio is developing a fibroblast-directed cell-engineering platform that utilizes lipid nanoparticle (LNP) encapsulated mRNA to simultaneously overexpress Meflin (ISLR) and a decoy IL-33 receptor (dST2). Meflin is a protein that marks anti-fibrotic fibroblast subsets and inhibits myofibroblast differentiation and collagen deposition. The decoy ST2 receptor (dST2) acts by sequestering IL-33, an alarmin that promotes type-2 (Th2) inflammation and pro-fibrotic fibroblast activation. By combining these two mechanisms, the therapy aims to reprogram pathogenic fibroblasts and restore tissue homeostasis in idiopathic pulmonary fibrosis (IPF) and other fibro-inflammatory diseases.

Other names: Meflin and IL-33 decoy ST2 LNP-mRNAMeflin + dST2 LNP-mRNA

Targets

ISLR (Immunoglobulin superfamily containing leucine-rich repeat protein)IL1RL1 (Interleukin 1 receptor-like 1 protein)IL33 (IL-33)

Beyond the preview

Go deeper on meflin + IL-33 decoy ST2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on meflin + IL-33 decoy ST2.

Explore the full profile